SynthesisBMJ paediatrics open2025
Cost and economic burden associated with caring for children with Down syndrome: a systematic review.
Synthesis in BMJ paediatrics open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo summarise the direct and indirect cost incurred by the family and to evaluate the economic burden of caring for children with Down syndrome (DS).
methodsA systematic review was carried out following the Joanna Briggs guidelines. The English language studies published between 2000 and August 2024 were searched in seven databases, grey literature sources and references of the included studies. The studies were included if they assessed the cost of caring for DS children (< 18 years) or described the perception of the parents regarding the financial burden. This review included observational, longitudinal, mixed-methods and qualitative studies. Two reviewers independently screened the studies, extracted the data using a custom-made form and assessed the critical appraisal using JBI checklists. The mean and/or median costs were inflated to January 2025 and reported in US$, and the data were narratively synthesised. Thematic analysis was performed for the qualitative data.
resultsThe search retrieved 5652 records, of which 24 studies were included. A consistent higher cost was reported for DS children as compared with non-DS children, eg, cost associated with prescription drug claims was six times higher (US$2869 vs US$413, respectively). Additionally, there was a higher cost of caring for DS infants (eg, US$3453) as compared with the older (13-17 years: US$1157) DS children. Qualitative findings suggest that families incur additional medical, education and rehabilitation expenses, resulting in financial burden.
conclusionConsidering the higher financial burden, the creation of an appropriate system of care and support mechanisms may alleviate the burden and reduce the cost of healthcare. Findings highlight the gap in research and need for standardised approaches to cost evaluation. PROSPERO REGISTRATION NUMBER: CRD42021265312.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.